irinotecan has been researched along with Intestinal Perforation in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Boku, N; Kanemitsu, Y; Shida, D; Takashima, A; Tanabe, T; Tsukamoto, S; Yoshida, T | 1 |
| Almeida, PHRF; Andrade, EIG; Cherchiglia, ML; da Silva, WC; de Araujo, VE; de Assis Acurcio, F; Dos Santos, JBR; Godman, B; Kurdi, A; Lima, EMEA; Silva, MRRD | 1 |
| Baba, H; Baba, Y; Etoh, K; Ishimoto, T; Iwagami, S; Iwatsuki, M; Miyamoto, Y; Murata, A; Sakamoto, Y; Shigaki, H; Sugihara, H; Watanabe, M; Yoshida, N | 1 |
| Havre, RF; Kalaitzakis, E; Meisner, S; Willemoe, GL | 1 |
| Carpenter, W; Li, L; Meyerhardt, JA; Sanoff, HK; Schrag, D | 1 |
| Ishiguro, A; Kudo, T; Mitobe, S; Munakata, M; Okada, R; Sakata, Y; Shitara, K; Tomioka, R; Yokoyama, S | 1 |
1 review(s) available for irinotecan and Intestinal Perforation
| Article | Year |
|---|---|
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Cetuximab; Colorectal Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Fees, Pharmaceutical; Fluorouracil; Humans; Hypertension; Incidence; Intestinal Perforation; Irinotecan; Oxaliplatin; Panitumumab; Reimbursement Mechanisms; Response Evaluation Criteria in Solid Tumors | 2018 |
5 other study(ies) available for irinotecan and Intestinal Perforation
| Article | Year |
|---|---|
Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Panitumumab; Regression Analysis; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate | 2021 |
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive System Surgical Procedures; Female; Fluorouracil; Humans; Intestinal Obstruction; Intestinal Perforation; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Risk Factors | 2014 |
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Diseases; Colonic Neoplasms; Colonic Polyps; Colonoscopy; Endoscopic Mucosal Resection; Female; Fluorouracil; Humans; Intestinal Perforation; Irinotecan; Leucovorin | 2016 |
Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorectal Neoplasms; Comorbidity; Female; Humans; Intestinal Perforation; Irinotecan; Kaplan-Meier Estimate; Male; Medicare; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stroke; Survival Rate; United States | 2012 |
[Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cecal Diseases; Cisplatin; Colonoscopy; Drainage; Drug Administration Schedule; Fatal Outcome; Female; Humans; Intestinal Perforation; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pleural Effusion, Malignant | 2006 |